SAR and QSAR in Environmental Research
暂无分享,去创建一个
B. A. Fowler | B. Fowler | J. Fisher | J. Osterloh | M. Mumtaz | P. Ruiz | J. D. Osterloh | J. Fisher | M. Mumtaz | P. Ruiz
[1] G. Nordberg,et al. A kinetic model of cadmium metabolism in the human being. , 1978, Environmental research.
[2] Jeffrey Fisher,et al. Interpreting NHANES biomonitoring data, cadmium. , 2010, Toxicology letters.
[3] Michigan.,et al. Toxicological profile for dichloropropenes , 2008 .
[4] H J Clewell,et al. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[5] A J Bailer,et al. An introduction to the use of physiologically based pharmacokinetic models in risk assessment , 1997, Statistical methods in medical research.
[6] H. El-Masri,et al. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[7] M. Caza,et al. A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. I. Development and validation of the model using experimental data in rats. , 2001, Toxicology and applied pharmacology.
[8] Lars Järup,et al. Hazards of heavy metal contamination. , 2003, British medical bulletin.
[9] M E Andersen,et al. Physiologically based pharmacokinetics and cancer risk assessment. , 1994, Environmental health perspectives.
[10] M. Caza,et al. A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. II. Application and validation of the model in humans. , 2001, Toxicology and applied pharmacology.
[11] K. Rissanen,et al. Elimination of 203Hg-methylmercury in man. , 1971, Annals of clinical research.
[12] C. Steinmaus,et al. Dietary Intake and Arsenic Methylation in a U.S. Population , 2005, Environmental health perspectives.
[13] Max Henrion,et al. The Propagation and Analysis of Uncertainty , 1990 .
[14] J. Hightower,et al. Mercury levels in high-end consumers of fish. , 2002, Environmental health perspectives.
[15] G. Diamond,et al. Pharmacokinetics/Pharmacodynamics (PK/PD) Modeling of Risks of Kidney Toxicity from Exposure to Cadmium: Estimates of Dietary Risks in the U.S. Population , 2003, Journal of toxicology and environmental health. Part A.
[16] L Järup,et al. Health effects of cadmium exposure--a review of the literature and a risk estimate. , 1998, Scandinavian journal of work, environment & health.
[17] M. Andersen,et al. The use of inhalation techniques to assess the kinetic constants of 1,1-dichloroethylene metabolism. , 1979, Toxicology and applied pharmacology.
[18] D. Mergler,et al. Fish consumption and bioindicators of inorganic mercury exposure. , 2007, The Science of the total environment.
[19] Harvey J Clewell,et al. Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene , 2005, Critical reviews in toxicology.
[20] J. O. Snihs,et al. Whole-body measurements on the distribution of mercury-203 in humans after oral intake of methylradiomercury nitrate. , 1970, Acta radiologica: therapy, physics, biology.
[21] James M. Hassett,et al. URINARY CADMIUM ELIMINATION AS A BIOMARKER OF EXPOSURE FOR EVALUATING A CADMIUM DIETARY EXPOSURE - BIOKINETICS MODEL , 2001, Journal of toxicology and environmental health. Part A.
[22] J. O. Snihs,et al. Metabolism of methyl mercury (203Hg) compounds in man. , 1969, Archives of environmental health.
[23] J W Fisher,et al. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.